Search results
21 sie 2018 · For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting).
The adoption of the USPSTF guidelines expands the recommended options for cervical cancer screening in average-risk individuals aged 30 years and older to include screening every 5 years with primary high-risk human papillomavirus (hrHPV) testing.
21 sie 2018 · Screening with cervical cytology alone, primary testing for hrHPV alone, or both at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. Clinicians should focus on ensuring that women receive adequate screening, appropriate evaluation of abnormal results, and indicated treatment, regardless of which ...
10 mar 2022 · Cervical Cancer: Screening. An Update for This Topic is In Progress. LAST UPDATED: Mar 10, 2022. The Task Force keeps recommendations as current as possible by routinely updating existing recommendations and developing new recommendations. A multistep process is followed for each recommendation.
6 mar 2023 · This guidance document addresses key questions related to cervical cancer screening and management and introduces the most recently updated screening guidelines, risk-based management for screening and surveillance, as well as methodologies for the diagnosis of cervical cancer.
15 kwi 2003 · This statement summarizes the current U.S. Preventive Services Task Force (USPSTF) recommendations on screening for cervical cancer and the supporting scientific evidence.
ASCCP endorses the United States Preventative Services Task Force (USPSTF) cervical cancer screening guidelines. ASCCP supports the American Cancer Society (ACS) cervical cancer screening guidelines. Endorsement of a peer organization’s clinical document denotes that ASCCP fully supports the clinical guidance in the document.
